Supporting Your Patient
Information for patients diagnosed with Neuroendocrine Cancer.
Being diagnosed with cancer is one of the greatest challenges anyone can face. Being diagnosed with a rare or uncommon cancer can have additional consequences, not least in terms of awareness, early diagnosis and access to expertise.
Feelings of isolation, fear, uncertainty and anxiety are not uncommon.
NCUK exists to support patients and their loved ones with the physical and psychological burden of Neuroendocrine Cancers. Working alongside HCPs and clinical teams, we are an additional source of support and information – often simply acting as a sounding board for patients – to go through information they have received (where they want to check their understanding) and providing reassurance where needed.
We have a number of resources and services that can be used, in your clinical practice, to assist in supporting your patients :
Compassionate Welfare Grant
We are very aware that there are costs associated with getting to and from hospital appointments, especially for investigations and treatments. We really want to be able to support our community, and have therefore developed a compassionate travel welfare fund. The objective of this fund is to provide financial support to Neuroendocrine Cancer patients and, where required, an accompanying family member, clinical advocate or carer, for travel to expert clinical centres to access treatment related scans and treatments.
The request for financial support must come from one of your specialist clinical team and there is an application form to complete below.
Clinical teams will be made aware of this fund. We truly hope that this will provide some relief to those who need it.
*This grant was made possible through the support of AAA (A Novartis Company).
Compassionate Welfare Grant Application Form
Neuroendocrine Cancer UK is a UK wide charity solely dedicated to providing support and information to those affected by Neuroendocrine Cancer.
Subscribe to our Newsletter to stay update with our latest news.